作为Q4成果节节估计数,生物ventus的股份猛增22.4%,JP摩根的评级提升。 Bioventus shares surge 22.4% as Q4 results beat estimates, with JPMorgan upgrading its rating.

医疗设备公司 Bioventus 的股价在盘前交易中上涨了 22.4%，此前该公司报告了第四季度净亏损收窄和收入增加，超过了市场预期。 Medical device company Bioventus saw its shares rise by 22.4% in pre-market trading after reporting a narrower net loss and higher revenues for Q4, beating market estimates. 该公司预测,2025财政年度经调整的每股收益为64美元至68美元,销售净额为5.6亿美元至5.7亿美元,均高于分析师的预期。 The company projects FY 2025 adjusted earnings per share of $0.64 to $0.68 and net sales of $560 million to $570 million, both above analyst expectations. 此外,JPMorgan将Bioventus的评级提高到“中性”,将其价格目标提高到13.00美元。 Additionally, JPMorgan raised Bioventus' rating to "neutral" and increased its price target to $13.00.